Converge Bio

The company's business model is centered on providing its AI platform as a B2B service to biotech and pharmaceutical companies, acting as an "AI-Lab partner" to support their research and development efforts. Clients, which include over a dozen pharma and biotech companies such as Teva, can integrate the platform directly into their existing workflows. This allows scientists to obtain actionable outputs without needing to write code or build their own infrastructure. The platform combines multiple proprietary large language models (LLMs) trained on biological data—including DNA, RNA, and protein sequences—to offer solutions across the drug development lifecycle. Key applications include target and biomarker discovery, antibody design and engineering, and protein manufacturing optimization. For instance, the platform can identify disease-driving targets, engineer antibodies with improved specificity, and optimize protein sequences to increase manufacturing yields. Customers can also use their own proprietary data to create fine-tuned, private instances of the models while retaining full data ownership.

Converge Bio has demonstrated commercial traction and scientific results, completing over 40 programs with partners in its first year, achieving milestones such as discovering antibodies with high affinities and improving protein yields by 4 to 7 times. The company's technology is applied across therapeutic areas like oncology, neurodegenerative diseases, and autoimmune diseases. In November 2024, the company announced a $5.5 million seed funding round. This was followed by a $25 million Series A round in January 2026, led by Bessemer Venture Partners with participation from TLV Partners, Vintage Investment Partners, and executives from Meta, OpenAI, and Wiz, bringing its total funding to over $30 million. This capital is intended to expand the platform's capabilities and scale the team.